https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
BCR free survival after 12 months was 100% and 88,2%, after 20 months - 92,3% and 86,4%, p=0,04. PSM ratesin the study group were notsignificantly different depending on the type of surgery 13,9% in robotic-assisted approach and 15,4% in retropubic approach, p=0,75. CONCLUSIONS Relatively favorable histopathological outcomes and BCR free survival can be achieved after nsRP. However, obtained results could not be considered optimal and clearly indicate the need for further improvement of preoperative planning and intrao
Beğen
Yorum Yap
Paylaş
